Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Cancer Res ; 24(22): 5602-5609, 2018 11 15.
Article in English | MEDLINE | ID: mdl-29898991

ABSTRACT

Purpose: The accumulation of emergent RAS mutations during anti-EGFR therapy is of interest as a mechanism for acquired resistance to anti-EGFR treatment. Plasma analysis of circulating tumor (ct) DNA is a minimally invasive and highly sensitive method to determine RAS mutational status.Experimental Design: This biomarker analysis of the global phase III ASPECCT study used next-generation sequencing to detect expanded RAS ctDNA mutations in panitumumab-treated patients. Plasma samples collected at baseline and posttreatment were analyzed categorically for the presence of RAS mutations by the PlasmaSelect-R 64-gene panel at 0.1% sensitivity.Results: Among panitumumab-treated patients with evaluable plasma samples at baseline (n = 238), 188 (79%) were wild-type (WT) RAS, and 50 (21%) were mutant RAS Of the 188 patients with baseline ctDNA WT RAS status, 164 had evaluable posttreatment results with a 32% rate of emergent RAS mutations. The median overall survival for WT and RAS mutant status by ctDNA at baseline was 13.7 (95% confidence interval, 11.5-15.4) and 7.9 months (6.4-9.6), respectively (P < 0.0001). Clinical outcomes were not significantly different between patients with and without emergent ctDNA RAS mutations.Conclusions: Although patients with baseline ctDNA RAS mutations had worse outcomes than patients who were WT RAS before initiating treatment, emergent ctDNA RAS mutations were not associated with less favorable patient outcomes in panitumumab-treated patients. Further research is needed to determine a clinically relevant threshold for baseline and emergent ctDNA RAS mutations. Clin Cancer Res; 24(22); 5602-9. ©2018 AACR.


Subject(s)
Biomarkers, Tumor , Circulating Tumor DNA , Colorectal Neoplasms/genetics , Drug Resistance, Neoplasm/drug effects , Genes, ras , Mutation , Alleles , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Clinical Trials, Phase III as Topic , Colorectal Neoplasms/blood , Colorectal Neoplasms/drug therapy , Colorectal Neoplasms/mortality , DNA Mutational Analysis , Drug Resistance, Neoplasm/genetics , Gene Frequency , High-Throughput Nucleotide Sequencing , Humans , Liquid Biopsy , Prognosis
2.
J Cell Biol ; 167(3): 531-43, 2004 Nov 08.
Article in English | MEDLINE | ID: mdl-15534004

ABSTRACT

The AP-1B clathrin adaptor complex is responsible for the polarized transport of many basolateral membrane proteins in epithelial cells. Localization of AP-1B to recycling endosomes (REs) along with other components (exocyst subunits and Rab8) involved in AP-1B-dependent transport suggested that RE might be an intermediate between the Golgi and the plasma membrane. Although the involvement of endosomes in the secretory pathway has long been suspected, we now present direct evidence using four independent methods that REs play a role in basolateral transport in MDCK cells. Newly synthesized AP-1B-dependent cargo, vesicular stomatitis virus glycoprotein G (VSV-G), was found by video microscopy, immunoelectron microscopy, and cell fractionation to enter transferrin-positive REs within a few minutes after exit from the trans-Golgi network. Although transient, RE entry appears essential because enzymatic inactivation of REs blocked VSV-G delivery to the cell surface. Because an apically targeted VSV-G mutant behaved similarly, these results suggest that REs not only serve as an intermediate but also as a common site for polarized sorting on the endocytic and secretory pathways.


Subject(s)
Cell Membrane/metabolism , Endocytosis , Endosomes/physiology , Golgi Apparatus/metabolism , Protein Transport , Adaptor Protein Complex 1/metabolism , Animals , Cell Line , Dogs , Membrane Glycoproteins/metabolism , Microscopy, Fluorescence , Microscopy, Video , Transferrin , Viral Envelope Proteins/metabolism
3.
J Cell Biol ; 163(2): 339-50, 2003 Oct 27.
Article in English | MEDLINE | ID: mdl-14581456

ABSTRACT

The AP-1B clathrin adaptor complex plays a key role in the recognition and intracellular transport of many membrane proteins destined for the basolateral surface of epithelial cells. However, little is known about other components that act in conjunction with AP-1B. We found that the Rab8 GTPase is one such component. Expression of a constitutively activated GTP hydrolysis mutant selectively inhibited basolateral (but not apical) transport of newly synthesized membrane proteins. Moreover, the effects were limited to AP-1B-dependent basolateral cargo; basolateral transport of proteins containing dileucine targeting motifs that do not interact with AP-1B were targeted normally despite overexpression of mutant Rab8. Similar results were obtained for a dominant-negative allele of the Rho GTPase Cdc42, previously implicated in basolateral transport but now shown to be selective for the AP-1B pathway. Rab8-GFP was localized to membranes in the TGN-recycling endosome, together with AP-1B complexes and the closely related but ubiquitously expressed AP-1A complex. However, expression of active Rab8 caused a selective dissociation of AP-1B complexes, reflecting the specificity of Rab8 for AP-1B-dependent transport.


Subject(s)
Cell Polarity/physiology , GTP Phosphohydrolases/metabolism , Kidney/cytology , rab GTP-Binding Proteins/metabolism , Adaptor Protein Complex 1/metabolism , Adaptor Protein Complex gamma Subunits/metabolism , Adenoviridae/genetics , Adenoviridae/metabolism , Animals , Biological Transport , Biomarkers , Cell Line , Dogs , Endosomes/metabolism , Enzyme Activation , GTP Phosphohydrolases/ultrastructure , Gene Expression , Mutation , Transferrin/pharmacokinetics , cdc42 GTP-Binding Protein/metabolism , rab GTP-Binding Proteins/genetics , rab GTP-Binding Proteins/ultrastructure , trans-Golgi Network/metabolism , trans-Golgi Network/ultrastructure
SELECTION OF CITATIONS
SEARCH DETAIL
...